Minovia Therapeutics

Company Overview

Snapshot

Founded in December 2011 by Natalie Yivgi-Ohana, Minovia Therapeutics operates with 11–50 employees. The company has raised a total of $28.35 million across 5 funding rounds from 3 investors. In June 2025, Minovia Therapeutics became public on NASDAQ through a proposed business combination with Launch One Acquisition Corp.

Business overview

Minovia Therapeutics is a Health Tech & Life Sciences company focused on treating mitochondrial diseases through its proprietary Mitochondrial Augmentation Therapy (MAT) platform. The company's core technology involves a cell therapy approach designed to address a broad range of indications stemming from mitochondrial dysfunction, including rare diseases and age-related conditions. Minovia serves the pharmaceutical and healthcare markets, with an initial clinical focus on rare mitochondrial diseases for which no approved treatments currently exist. The company is actively engaged in clinical trials, including a Phase 1/2 study for Pearson Syndrome.

Strategic signal

In February 2026, news emerged that the proposed business combination between Minovia Therapeutics and Launch One Acquisition Corp., which aimed to create a Nasdaq-listed mitochondrial therapy company, would not proceed. This development indicates a significant shift in Minovia's immediate public market strategy and signals a potential re-evaluation of its path to liquidity or alternative financing mechanisms for investors.

Company Intelligence Q&A

What is Minovia Therapeutics' primary focus?

Minovia Therapeutics focuses on treating mitochondrial diseases using its proprietary Mitochondrial Augmentation Therapy (MAT) platform, which is a cell therapy approach.

When did Minovia Therapeutics become a public company?

Minovia Therapeutics became public on NASDAQ in June 2025 through a proposed business combination with Launch One Acquisition Corp.

What significant corporate development occurred in February 2026?

In February 2026, Launch One Acquisition Corp. announced that it would not merge with Minovia Therapeutics, indicating the termination of their proposed business combination.

Has Minovia Therapeutics received any regulatory clearances recently?

In April 2025, Minovia Therapeutics announced FDA clearance of its second IND application for a.

What was a key strategic collaboration for Minovia Therapeutics in 2021?

In July 2021, Astellas and Minovia Therapeutics announced a strategic collaboration focused on novel mitochondrial cell therapy programs.